January 22, 2016

September 24, 2014

Pennsylvania-based drug maker Shire Pharmaceuticals agreed to pay $56.5 million to settle charges it violated the False Claims Act through improper marketing and promotion of several drugs used to treat attention deficit hyperactivity disorder (ADHD) and ulcerative colitis. The government’s allegations arose from two whistleblower lawsuit filed by several former Shire employees under the qui tam provisions of the False Claims Act. Whistleblower Insider

*     *     *

If you would like more information or would like to speak to a member of Constantine Cannon’s whistleblower lawyer team, please click here.